Literature DB >> 15322279

On the modeling of snake venom serine proteinase interactions with benzamidine-based thrombin inhibitors.

Elsa S Henriques1, Nelson Fonseca, Maria João Ramos.   

Abstract

Pit viper venoms contain a number of serine proteinases that exhibit one or more thrombin-like activities on fibrinogen and platelets, this being the case for the kinin-releasing and fibrinogen-clotting KN-BJ from the venom of Bothrops jararaca. A three-dimensional structural model of the KN-BJ2 serine proteinase was built by homology modeling using the snake venom plasminogen activator TSV-PA as a major template and porcine kallikrein as additional structural support. A set of intrinsic buried waters was included in the model and its behavior under dynamic conditions was molecular dynamics simulated, revealing a most interesting similarity pattern to kallikrein. The benzamidine-based thrombin inhibitors alpha-NAPAP, 3-TAPAP, and 4-TAPAP were docked into the refined model, allowing for a more insightful functional characterization of the enzyme and a better understanding of the reported comparatively low affinity of KN-BJ2 toward those inhibitors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322279      PMCID: PMC2280023          DOI: 10.1110/ps.04746804

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  29 in total

Review 1.  New anticoagulant drugs.

Authors:  J I Weitz; J Hirsh
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  Crystallization of bothrombin, a fibrinogen-converting serine protease isolated from the venom of Bothrops jararaca.

Authors:  L Watanabe; D F Vieira; R K Bortoleto; R K Arni
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2002-05-29

3.  Development and validation of a genetic algorithm for flexible docking.

Authors:  G Jones; P Willett; R C Glen; A R Leach; R Taylor
Journal:  J Mol Biol       Date:  1997-04-04       Impact factor: 5.469

4.  Profile analysis.

Authors:  M Gribskov; R Lüthy; D Eisenberg
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

5.  Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features.

Authors:  W Kabsch; C Sander
Journal:  Biopolymers       Date:  1983-12       Impact factor: 2.505

6.  Refined 2.5 A X-ray crystal structure of the complex formed by porcine kallikrein A and the bovine pancreatic trypsin inhibitor. Crystallization, Patterson search, structure determination, refinement, structure and comparison with its components and with the bovine trypsin-pancreatic trypsin inhibitor complex.

Authors:  Z Chen; W Bode
Journal:  J Mol Biol       Date:  1983-02-25       Impact factor: 5.469

7.  Inhibition of bovine and human thrombins by derivatives of benzamidine.

Authors:  J Stürzebecher; P Walsmann; B Voigt; G Wagner
Journal:  Thromb Res       Date:  1984-12-01       Impact factor: 3.944

8.  Purification and characterization of a kinin-releasing and fibrinogen-clotting serine proteinase (KN-BJ) from the venom of Bothrops jararaca, and molecular cloning and sequence analysis of its cDNA.

Authors:  S M Serrano; Y Hagiwara; N Murayama; S Higuchi; R Mentele; C A Sampaio; A C Camargo; E Fink
Journal:  Eur J Biochem       Date:  1998-02-01

9.  Buried water in homologous serine proteases.

Authors:  U Sreenivasan; P H Axelsen
Journal:  Biochemistry       Date:  1992-12-29       Impact factor: 3.162

10.  The crystal structure of the novel snake venom plasminogen activator TSV-PA: a prototype structure for snake venom serine proteinases.

Authors:  M A Parry; U Jacob; R Huber; A Wisner; C Bon; W Bode
Journal:  Structure       Date:  1998-09-15       Impact factor: 5.006

View more
  1 in total

1.  Antimicrobial and anticoagulant activities of N-chlorotaurine, N,N-dichloro-2,2-dimethyltaurine, and N-monochloro-2,2-dimethyltaurine in human blood.

Authors:  C Martini; A Hammerer-Lercher; M Zuck; A Jekle; D Debabov; M Anderson; M Nagl
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.